Pfizer invests in a Swiss biotech start-up
Anjarium Biosciences raises CHF 55.5M Series A financing to develop next-generation non-viral gene therapies
30-Sep-2021 -
Anjarium Biosciences AG, a biotech start-up focused on creating and delivering a new class of non-viral gene therapies announced the closing of a CHF55.5M ($61M) Series A financing. The round was co-led by Abingworth and Gimv, with significant participation from Omega Funds, Pfizer Ventures and ...
gene therapy
Series A financing